China · Delayed Price · Currency is CNY Cathay Biotech Statistics
Total Valuation
Cathay Biotech has a market cap or net worth of CNY 30.38 billion. The enterprise value is 25.68 billion.
| Market Cap | 30.38B |
| Enterprise Value | 25.68B |
Important Dates
The next estimated earnings date is Friday, August 14, 2026.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | Aug 1, 2025 |
Share Statistics
Cathay Biotech has 720.66 million shares outstanding. The number of shares has increased by 22.28% in one year.
| Current Share Class | 720.66M |
| Shares Outstanding | 720.66M |
| Shares Change (YoY) | +22.28% |
| Shares Change (QoQ) | +0.45% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 14.85% |
| Float | 263.62M |
Valuation Ratios
The trailing PE ratio is 51.14 and the forward PE ratio is 34.77.
| PE Ratio | 51.14 |
| Forward PE | 34.77 |
| PS Ratio | 8.95 |
| PB Ratio | 1.41 |
| P/TBV Ratio | 1.77 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 102.77 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 24.31, with an EV/FCF ratio of -55.42.
| EV / Earnings | 43.57 |
| EV / Sales | 7.57 |
| EV / EBITDA | 24.31 |
| EV / EBIT | 34.66 |
| EV / FCF | -55.42 |
Financial Position
The company has a current ratio of 5.11, with a Debt / Equity ratio of 0.05.
| Current Ratio | 5.11 |
| Quick Ratio | 4.26 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | 1.21 |
| Debt / FCF | -2.36 |
| Interest Coverage | 67.66 |
Financial Efficiency
Return on equity (ROE) is 2.67% and return on invested capital (ROIC) is 3.96%.
| Return on Equity (ROE) | 2.67% |
| Return on Assets (ROA) | 1.51% |
| Return on Invested Capital (ROIC) | 3.96% |
| Return on Capital Employed (ROCE) | 2.68% |
| Weighted Average Cost of Capital (WACC) | 7.32% |
| Revenue Per Employee | 1.93M |
| Profits Per Employee | 334,745 |
| Employee Count | 1,761 |
| Asset Turnover | 0.14 |
| Inventory Turnover | 1.83 |
Taxes
In the past 12 months, Cathay Biotech has paid 94.63 million in taxes.
| Income Tax | 94.63M |
| Effective Tax Rate | 14.25% |
Stock Price Statistics
The stock price has decreased by -9.74% in the last 52 weeks. The beta is 0.60, so Cathay Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.60 |
| 52-Week Price Change | -9.74% |
| 50-Day Moving Average | 48.58 |
| 200-Day Moving Average | 50.69 |
| Relative Strength Index (RSI) | 28.09 |
| Average Volume (20 Days) | 6,060,797 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Cathay Biotech had revenue of CNY 3.39 billion and earned 589.49 million in profits. Earnings per share was 0.82.
| Revenue | 3.39B |
| Gross Profit | 1.05B |
| Operating Income | 594.83M |
| Pretax Income | 664.18M |
| Net Income | 589.49M |
| EBITDA | 902.65M |
| EBIT | 594.83M |
| Earnings Per Share (EPS) | 0.82 |
Balance Sheet
The company has 9.41 billion in cash and 1.09 billion in debt, with a net cash position of 8.31 billion or 11.53 per share.
| Cash & Cash Equivalents | 9.41B |
| Total Debt | 1.09B |
| Net Cash | 8.31B |
| Net Cash Per Share | 11.53 |
| Equity (Book Value) | 21.49B |
| Book Value Per Share | 24.80 |
| Working Capital | 9.86B |
Cash Flow
In the last 12 months, operating cash flow was 295.64 million and capital expenditures -759.08 million, giving a free cash flow of -463.44 million.
| Operating Cash Flow | 295.64M |
| Capital Expenditures | -759.08M |
| Depreciation & Amortization | 307.83M |
| Net Borrowing | -506.54M |
| Free Cash Flow | -463.44M |
| FCF Per Share | -0.64 |
Margins
Gross margin is 30.81%, with operating and profit margins of 17.53% and 17.37%.
| Gross Margin | 30.81% |
| Operating Margin | 17.53% |
| Pretax Margin | 19.57% |
| Profit Margin | 17.37% |
| EBITDA Margin | 26.60% |
| EBIT Margin | 17.53% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.45, which amounts to a dividend yield of 1.04%.
| Dividend Per Share | 0.45 |
| Dividend Yield | 1.04% |
| Dividend Growth (YoY) | 110.52% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 51.44% |
| Buyback Yield | -22.28% |
| Shareholder Yield | -21.25% |
| Earnings Yield | 1.94% |
| FCF Yield | -1.53% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 20, 2022. It was a forward split with a ratio of 1.4.
| Last Split Date | Jul 20, 2022 |
| Split Type | Forward |
| Split Ratio | 1.4 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 6 |